SCHEMBL25912482

SCHEMBL25912482

CCC(=O)N1CC2(CCN(C(C)C)C2=O)C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.39
OPRM1 P35372 1/20 0.38
ACACB O00763 2/20 0.34
ACACA Q13085 2/20 0.34
AOC2 O75106 1/20 0.33
BLM P54132 1/20 0.33
EPHX2 P34913 5/20 0.32
EPHX1 P07099 2/20 0.32
CHRM4 P08173 1/20 0.32
CHRM1 P11229 1/20 0.32
POLB P06746 1/20 0.31
ALOX15 P16050 1/20 0.31
PRMT1 Q99873 1/20 0.30
CRBN Q96SW2 1/20 0.30
CHRNB2 P17787 1/20 0.30
CHRNA3 P32297 1/20 0.30
CHRNA4 P43681 1/20 0.30
CHRNB3 Q05901 1/20 0.30
CHRNA6 Q15825 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25919798 0.93 OPRM1 (0.43) ALDH1A1LMNAOPRM1ACACBACACA
SCHEMBL25912761 0.91 ALDH1A1 (0.39) ALDH1A1LMNAOPRM1ACACBACACA
SCHEMBL23338590 0.81 ACACB (0.33) ACACBACACAAOC2CRBNCHRNB2
SCHEMBL23342178 0.77 CRBN (0.36) ACACBACACAAOC2CRBNCHRNB2
SCHEMBL12758825 0.75 SMN1; SMN2 (0.36) OPRM1AOC2PRMT1
SCHEMBL12832224 0.75 CHRM2 (0.35) OPRM1AOC2PRMT1
SCHEMBL17118711 0.75 CYP3A4 (0.38) ALDH1A1OPRM1CRBN
SCHEMBL25920033 0.74 SMN1; SMN2 (0.39) ALDH1A1ACACBACACAALOX15
SCHEMBL23342004 0.74 ACACB (0.38) ACACBACACAAOC2CRBN
SCHEMBL23342007 0.73 AOC2 (0.34) ALDH1A1ACACBACACAAOC2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS KRAS, HRAS, MTOR ALDH1A1 4528/4885LMNA 1680/4885OPRM1 4485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.